We welcome the report and process underway to update the Global Action Plan, while noting with concern the challenges hindering an effective response. The global pipeline for antibiotics remains nearly empty—therefore we must not only discover new antibiotics but optimize existing ones. We must also ensure there is evidence and appropriate formulations to provide children and babies with timely treatment.

And we must overcome the crisis of access to antibiotics affecting low- and middle-income countries. New GARDP research from a study of eight LMICs showed that only 6.9% of carbapenem-resistant gram-negative infections had potentially appropriate antibiotics available.

We urge Member States to not lose sight of the short- and long-term consequences of AMR and to commit the resources needed to address this challenge comprehensively and globally.